Symptomatic Middle Ear and Cranial Sinus Barotraumas As a Complication of Hyperbaric Oxygen Treatment
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pediatric Trauma Imaging from Head To
High yield pediatric imaging Pediatric Trauma and other Pediatric Emergencies Lynn Ansley Fordham, MD, FACR, FAIUM, FAAWR UNC School of Medicine Department of Radiology Division Chief Pediatric Radiology Overview • Discuss epidemiology of pediatric trauma • Discuss unique aspects of skeletal trauma and fractures in children • Look at a few example of fractures • Review other common pediatric emergencies • Some Pollev Pollev.com\lynnfordham • Lots cases Keywords for PACs case review • PTF • TUBES AND LINES • Pre call cases peds Who to page for peds 2am Thursday morning? Faculty call shift 5pm to 8 am, for midnight to 8am, use prior day schedule Etiology of Skeletal Trauma in Children Significance of pediatric injuries • injuries 40% deaths in 1-4 year olds • injuries 90% deaths in 5-19 year olds Causes of Mortality in Childhood • MVA most common in all age groups • pedestrian (vs. auto 5-9) • bicycle • firearms • fires • drowning/ near drowning Causes of Morbidity in Childhood • falls – most common cause of injury in children • non-fatal MVAs • bicycle related trauma • trampolines • near drowning • other non-fatal injuries Trends over time • Decrease in death rates due to unintentional injuries – Carseats – Bicycle helmets • Increase in homicide rate • Increase in suicide rate MVA common injuries • depends on impact and seatbelt status • spine – craniocervical junction – thoracolumbar spine • pelvis • extremities • sternum rare in children Pediatric Fractures • Fractures related to the physis (growth plate) – Use Salter Harris classification -
What Chamber Operators Should Know About Ear Barotrauma (And How to Prevent It) Robert Sheffield, CHT and Kevin “Kip” Posey, CHT / June 2018
LEARN.HYPERBARICMEDICINE.COM International ATMO Education What Chamber Operators Should Know About Ear Barotrauma (and How to Prevent It) Robert Sheffield, CHT and Kevin “Kip” Posey, CHT / June 2018 INTRODUCTION Ear barotrauma (i.e. “ear block”, “ear squeeze”) is the most common complication of hyperbaric treatment. It occurs when the pressure in the hyperbaric chamber is greater than the pressure in the middle ear. It is prevented by patient assessment, patient education, and the appropriate actions of the chamber operator. The chamber operator has an important role in preventing ear barotrauma in hyperbaric patients. OBJECTIVES At the conclusion of this article, the reader will be able to: Describe the anatomy of the middle ear Explain the mechanism of ear barotrauma Describe 3 techniques to equalize middle ear pressure ANATOMY OF THE MIDDLE EAR The middle ear is an air space that separates the external ear canal from the inner ear. The eardrum, called the tympanic membrane (TM), vibrates when sound enters the ear canal. The vibration is transmitted to a series of bones in the middle ear. These bones transmit vibration to another membrane (the oval window) that separates the air‐filled middle ear from the fluid‐filled inner ear, where sound is sensed in the cochlea. The nasopharynx is the area behind the nose and above the palate. The Eustachian tubes open into this area. Because of the location of the Eustachian tube openings, the same things that cause nasal congestion (e.g. allergies, upper respiratory infection) can cause swelling around the opening of the Eustachian tubes, making it more difficult to equalize pressure in the middle ear. -
Critical Care in the Monoplace Hyperbaric Chamber
Critical Care in the Monoplace Hyperbaric Critical Care - Monoplace Chamber • 30 minutes, so only key points • Highly suggest critical care medicine is involved • Pitfalls Lindell K. Weaver, MD Intermountain Medical Center Murray, Utah, and • Ventilator and IV issues LDS Hospital Salt Lake City, Utah Key points Critical Care in the Monoplace Chamber • Weaver LK. Operational Use and Patient Care in the Monoplace Chamber. In: • Staff must be certified and experienced Resp Care Clinics of N Am-Hyperbaric Medicine, Part I. Moon R, McIntyre N, eds. Philadelphia, W.B. Saunders Company, March, 1999: 51-92 in CCM • Weaver LK. The treatment of critically ill patients with hyperbaric oxygen therapy. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, and Donovan JW, • Proximity to CCM services (ed). Critical care toxicology: diagnosis and management of the critically poisoned patient. Philadelphia: Elsevier Mosby; 2005:181-187. • Must have study patient in chamber • Weaver, LK. Critical care of patients needing hyperbaric oxygen. In: Thom SR and Neuman T, (ed). The physiology and medicine of hyperbaric oxygen therapy. quickly Philadelphia: Saunders/Elsevier, 2008:117-129. • Weaver LK. Management of critically ill patients in the monoplace hyperbaric chamber. In: Whelan HT, Kindwall E., Hyperbaric Medicine Practice, 4th ed.. • CCM equipment North Palm Beach, Florida: Best, Inc. 2017; 65-95. • Without certain modifications, treating • Gossett WA, Rockswold GL, Rockswold SB, Adkinson CD, Bergman TA, Quickel RR. The safe treatment, monitoring and management -
Natural Coral As a Biomaterial Revisited
American Journal of www.biomedgrid.com Biomedical Science & Research ISSN: 2642-1747 --------------------------------------------------------------------------------------------------------------------------------- Research Article Copy Right@ LH Yahia Natural Coral as a Biomaterial Revisited LH Yahia1*, G Bayade1 and Y Cirotteau2 1LIAB, Biomedical Engineering Institute, Polytechnique Montreal, Canada 2Neuilly Sur Seine, France *Corresponding author: LH Yahia, LIAB, Biomedical Engineering Institute, Polytechnique Montreal, Canada To Cite This Article: LH Yahia, G Bayade, Y Cirotteau. Natural Coral as a Biomaterial Revisited. Am J Biomed Sci & Res. 2021 - 13(6). AJBSR. MS.ID.001936. DOI: 10.34297/AJBSR.2021.13.001936. Received: July 07, 2021; Published: August 18, 2021 Abstract This paper first describes the state of the art of natural coral. The biocompatibility of different coral species has been reviewed and it has been consistently observed that apart from an initial transient inflammation, the coral shows no signs of intolerance in the short, medium, and long term. Immune rejection of coral implants was not found in any tissue examined. Other studies have shown that coral does not cause uncontrolled calcification of soft tissue and those implants placed under the periosteum are constantly resorbed and replaced by autogenous bone. The available porestudies size. show Thus, that it isthe hypothesized coral is not cytotoxic that a damaged and that bone it allows containing cell growth. both cancellous Thirdly, porosity and cortical and gradient bone can of be porosity better replacedin ceramics by isa graded/gradientexplained based on far from equilibrium thermodynamics. It is known that the bone cross-section from cancellous to cortical bone is non-uniform in porosity and in in vitro, animal, and clinical human studies. -
Avascular Necrosis As a Part of ‘Long COVID-19’ Sanjay R Agarwala,1 Mayank Vijayvargiya,2 Prashant Pandey2
Case report BMJ Case Rep: first published as 10.1136/bcr-2021-242101 on 2 July 2021. Downloaded from Avascular necrosis as a part of ‘long COVID-19’ Sanjay R Agarwala,1 Mayank Vijayvargiya,2 Prashant Pandey2 1Orthopaedics, PD Hinduja SUMMARY I or II, 92%–97% of the patients do not require National Hospital, Mumbai, ’Long COVID-19’ can affect different body systems. At surgery and can be managed with bisphosphonate Maharashtra, India present, avascular necrosis (AVN) as a sequalae of ’long therapy. Hence, it is crucial to diagnose AVN early 2Orthopaedics, PD Hinduja COVID-19’ has yet not been documented. By large- scale to decrease the morbidity and the requirement of National Hospital and Medical surgery. Research Centre, Mumbai, use of life- saving corticosteroids in COVID-19 cases, Here, we report three cases of symptomatic AVN Maharashtra, India we anticipate that there will be a resurgence of AVN cases. We report a series of three cases in which patients of the femoral head after being treated for COVID- Correspondence to developed AVN of the femoral head after being treated 19. This is the first case report of AVN as sequalae Dr Sanjay R Agarwala; for COVID-19 infection. The mean dose of prednisolone of ‘long COVID-19’. drsa2011@ gmail.com used in these cases was 758 mg (400–1250 mg), which is less than the mean cumulative dose of around 2000 CASE PRESENTATION Accepted 23 May 2021 mg steroid, documented in the literature as causative for Case 1 AVN. Patients were symptomatic and developed early A- 36- year old male patient was diagnosed with AVN presentation at a mean of 58 days after COVID-19 COVID-19 on 6 September 2020, for which the diagnosis as compared with the literature which shows patient was admitted in intensive care at another that it generally takes 6 months to 1 year to develop AVN hospital because of dropping saturation. -
Stage-Related Results in Treatment of Hip Osteonecrosis with Core-Decompression and Autologous Mesenchymal Stem Cells
Acta Orthop. Belg., 2015, 81, 406-412 ORIGINAL STUDY Stage-related results in treatment of hip osteonecrosis with core-decompression and autologous mesenchymal stem cells Pietro PERSIANI, Claudia DE CRISTO, Jole GRACI, Giovanni NOIA, Michele GURZÌ, Ciro VILLANI From Universitary Department of Anatomic, Histologic, Forensic and Locomotor Apparatus Sciences, Section of Locomotor Apparatus Sciences, Policlinico Umberto I, Sapienza University of Rome Our aim is to analyse the clinical outcome of a series thetic hip replacement. Therapy with glucocorti- of patients affected by avascular necrosis of the femo- coids and alcohol abuse are some of the main known ral head and treated with core-decompression tech- causative factors (21). Several pathophysiological nique and autologous stromal cells of the bone mechanisms were formulated about this pathology, marrow. including fat emboli, microvascular occlusion of We enrolled in our study 29 patients with 31 hips in epiphysis vessels and micro fracture of trabecular total affected by avascular necrosis of the femoral 13,18 head. bone ( ). An early diagnosis and a continuous The clinical and radiological outcome has been monitoring of patients with risk factors (corticoste- assessed through self-administered questionnaires roids therapy, alcoholism, or irradiated patients) are (HHS, VAS and SF12) X-ray and Magnetic Reso- very important in order to highlight the AVNFH nance. typical alteration as early as possible. Of all the examined hips, 25 showed a relief of the The treatment of osteonecrosis is one of the most symptoms and a resolution of the osteonecrosis, 11 of controversial subjects in the orthopaedic literature. these were at Stage I and 14 at Stage II. -
Consensus Conference, the ECHM
24 Diving and Hyperbaric Medicine Volume 47 No. 1 March 2017 Consensus Conference Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment Daniel Mathieu, Alessandro Marroni and Jacek Kot Abstract (Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving and Hyperbaric Medicine. 2017 March;47(1):24-32.) The tenth European Consensus Conference on Hyperbaric Medicine took place in April 2016, attended by a large delegation of experts from Europe and elsewhere. The focus of the meeting was the revision of the European Committee on Hyperbaric Medicine (ECHM) list of accepted indications for hyperbaric oxygen treatment (HBOT), based on a thorough review of the best available research and evidence-based medicine (EBM). For this scope, the modified GRADE system for evidence analysis, together with the DELPHI system for consensus evaluation, were adopted. The indications for HBOT, including those promulgated by the ECHM previously, were analysed by selected experts, based on an extensive review of the literature and of the available EBM studies. The indications were divided as follows: Type 1, where HBOT is strongly indicated as a primary treatment method, as it is supported by sufficiently strong evidence; Type 2, where HBOT is suggested as it is supported by acceptable levels of evidence; Type 3, where HBOT can be considered as a possible/optional measure, but it is not yet supported by sufficiently strong evidence. For each type, three levels of evidence were considered: A, when the number of randomised controlled trials (RCTs) is considered sufficient; B, when there are some RCTs in favour of the indication and there is ample expert consensus; C, when the conditions do not allow for proper RCTs but there is ample and international expert consensus. -
Clinical Management of Severe Acute Respiratory Infections When Novel Coronavirus Is Suspected: What to Do and What Not to Do
INTERIM GUIDANCE DOCUMENT Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do Introduction 2 Section 1. Early recognition and management 3 Section 2. Management of severe respiratory distress, hypoxemia and ARDS 6 Section 3. Management of septic shock 8 Section 4. Prevention of complications 9 References 10 Acknowledgements 12 Introduction The emergence of novel coronavirus in 2012 (see http://www.who.int/csr/disease/coronavirus_infections/en/index. html for the latest updates) has presented challenges for clinical management. Pneumonia has been the most common clinical presentation; five patients developed Acute Respira- tory Distress Syndrome (ARDS). Renal failure, pericarditis and disseminated intravascular coagulation (DIC) have also occurred. Our knowledge of the clinical features of coronavirus infection is limited and no virus-specific preven- tion or treatment (e.g. vaccine or antiviral drugs) is available. Thus, this interim guidance document aims to help clinicians with supportive management of patients who have acute respiratory failure and septic shock as a consequence of severe infection. Because other complications have been seen (renal failure, pericarditis, DIC, as above) clinicians should monitor for the development of these and other complications of severe infection and treat them according to local management guidelines. As all confirmed cases reported to date have occurred in adults, this document focuses on the care of adolescents and adults. Paediatric considerations will be added later. This document will be updated as more information becomes available and after the revised Surviving Sepsis Campaign Guidelines are published later this year (1). This document is for clinicians taking care of critically ill patients with severe acute respiratory infec- tion (SARI). -
Acute Chest Syndrome, Avascular Necrosis of Femur, and Pulmonary Embolism All at Once: an Unexpected Encounter in the First-Ever Admission of a Sickle Cell Patient
Open Access Case Report DOI: 10.7759/cureus.17656 Acute Chest Syndrome, Avascular Necrosis of Femur, and Pulmonary Embolism All at Once: An Unexpected Encounter in the First-Ever Admission of a Sickle Cell Patient Akhilesh Annadatha 1 , Dhruv Talwar 1 , Sourya Acharya 1 , Sunil Kumar 1 , Vivek Lahane 1 1. Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed University), Wardha, IND Corresponding author: Dhruv Talwar, [email protected] Abstract Acute chest syndrome (ACS) is defined as the radiological appearance of pulmonary infiltrates with fever or respiratory symptoms like chest pain, breathlessness, and cough in a patient with sickle cell disease (SCD). It is also a very common cause of mortality in sickle cell patients, if not identified in early stages and treated aggressively. Radiological image is similar to bacterial pneumonia, so sickle cell disease with a radiological picture similar to pneumonia and associated respiratory symptoms is known as acute chest syndrome. Pneumonia and infarction have been implicated in pathogenesis. The reason for the appearance of acute chest syndrome in patients with SCD is not established but some triggers like sepsis, presence of vaso- occlusive crises have been noted. When there is a block in the blood supply to the bone, patients with sickle cell disease may also develop avascular necrosis of the neck of the femur causing narrowing of joint and collapse of the bone. Patients with sickle cell disease have a baseline hypercoagulable state thereby predisposing the patient to develop deep vein thrombosis and pulmonary embolism. Here, we present a case of a 25-year-old SCD patient with a fairly stable course of the disease. -
Bilateral Diaphragm Paralysis and Sleep Apnoea Without Diurnal Respiratory Failure
Thorax: first published as 10.1136/thx.43.1.75 on 1 January 1988. Downloaded from Thorax 1988;43:75-77 Bilateral diaphragm paralysis and sleep apnoea without diurnal respiratory failure J R STRADLING, A R H WARLEY From the Osler Chest Unit, Churchill Hospital, OxJord This is a case history of a patient with isolated bilateral increased at 3 6 kPa (27 mm Hg) and was presumed to be due diaphragm paralysis. It is presented because it offers insight to basal atelectasis. into possible mechanisms of the respiratory failure which Two months later overnight oximetry was performed usually develops in this condition. (Biox 2A). The awake semirecumbent arterial oxygen satura- tion (Sao2) was 93%. Most of the night was spent with a Case report stable Sao2 ofabout 92%. During three periods of 20 minutes there were regular recurrent dips in Sao, (rate 45/hour) to The patient, now 40 years old, presented in 1973 with about 80% (lowest 69%), presumed to be associated with mesangiocapillary glomerulonephritis (hypocompliment- rapid eye movement (REM) sleep. At this stage no further aemic with C3 nephritic factor) and subsequently developed action was taken except to advise sleeping propped up. progressive renal failure. In 1978 classical neuralgic amyotro- Two full sleep studies were performed 12 and 18 months phy (brachial neuritis) occurred in both arms and remitted later. They gave similar results. The patient's height and over the next three months, his sister having had similar weight at this time were 1-9 m and 94 kg respectively. Awake episodes some years before. Four months later he underwent values of Pao, and Paco, in the semirecumbent posture were a successful cadaver renal transplant. -
Hyperbaric Oxygen Therapy (HBOT) Final Evidence Report
20, 2012 Health Technology Assessment Hyperbaric Oxygen Therapy (HBOT) for Tissue Damage, Including Wound Care and Treatment of Central Nervous System (CNS) Conditions Final Evidence Report February 15, 2013 Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia, WA 98504-2712 (360) 725-5126 hta.hca.wa.gov [email protected] Hyperbaric Oxygen Therapy (HBOT) for Tissue Damage, Including Wound Care and Treatment of Central Nervous System (CNS) Conditions A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – February 15, 2013 Acknowledgement This report was prepared by: Hayes, Inc. 157 S. Broad Street Suite 200 Lansdale, PA 19446 P: 215.855.0615 F: 215.855.5218 This report is intended to provide research assistance and general information only. It is not intended to be used as the sole basis for determining coverage policy or defining treatment protocols or medical modalities, nor should it be construed as providing medical advice regarding treatment of an individual’s specific case. Any decision regarding claims eligibility or benefits, or acquisition or use of a health technology is solely within the discretion of your organization. Hayes, Inc. assumes no responsibility or liability for such decisions. Hayes employees and contractors do not have material, professional, familial, or financial affiliations that create actual or potential conflicts of interest related to the preparation of this report. Prepared by Winifred Hayes, Inc. Page i February -
Contraindications and Relative Contraindications, and Complications That May Occur with And/Or During HBOT
HYPERBARIC OXYGEN THERAPY INDICATIONS, CONTRAINDICTIONS AND COMPLICATIONS Policy: This policy lists accepted conditions or indications for insurance reimbursement for Hyperbaric oxygen therapy (HBOT), contraindications and relative contraindications, and complications that may occur with and/or during HBOT. Additional information is provided regarding drug therapy with HBOT. 1.0 HYPERBARIC OXYGEN THERAPY (HBOT) ACCEPTED CONDITIONS FOR INSURANCE REIMBURSEMENT: 1.1 The following list includes the currently accepted conditions: A. Air or gas embolism B. Carbon monoxide/cyanide poisoning and smoke inhalation C. Crush injury/traumatic ischemia D. Decompression sickness E. Enhancement in healing in selected problem wounds F. Exceptional anemia resulting for blood loss G. Gas Gangrene(clostridial) H. Necrotizing soft tissue infections I. Refractory osteomyelitis J. Comprised skin grafts/flaps K. Radiation tissue damage L. Thermal burns 2.0 ABSOLUTE CONTRAINDICATIONS 2.1 Untreated pneumothorax A. Surgical relief of the pneumothorax before the HBOT treatment, if possible, removes the obstacle to treatment. 3.0 RELATIVE CONTRAINDICATIONS-- “Conditions in which caution must sometimes be observed but which are not necessarily a contraindication to HBOT.” (Kindwall, 1995) 3.1 History of spontaneous pneumothorax 3.2 Severe sinus infection 3.3 Upper respiratory infection 3.4 Asymptomatic pulmonary lesions on chest x-ray 3.5 Uncontrollable high fever (greater than 39C) 3.6 History of chest or ear surgery 3.7 Congenital spherocytosis 3.8 Any anemia or